The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
June 1st, 2019
In Indonesia, sentinel node biopsy (SNB) is not routinely performed for breast cancer surgery because of the limitation to provide radioisotope tracer and isosulfan or patent blue dye (PBD). To overcome this obstacle, we applied 1% methylene blue dye (MBD) as a single agent to map the sentinel nodes (SNs).
The application of one percent methylene blue dye as a single technique in breast cancer sentinel node biopsy. The overall goal of this procedure is to show the application of blue dye alone as a single technique for early breast cancer axillary node biopsy, using 1%methylene blue dye and to show how to isosulfan examination of sentinel nodes. Section one preparation of one percent methylene blue dye and the injection technique.
Section two sentinel node biopsy technique in breast conserving surgery. Section three. sentinel node biopsy technique in mastectomy.
Section four pathological examination of sentinel nodes. Section five intraoperative examination. Section six results.
Section seven conclusion.
View the full transcript and gain access to thousands of scientific videos
Overview
This article demonstrates the use of 1% methylene blue dye (MBD) as a standalone technique for sentinel node biopsy (SNB) in early breast cancer. The protocol details the preparation and injection of MBD, identification of sentinel nodes (SNs) during both breast conserving surgery (BCS) and mastectomy, and the subsequent pathological evaluation of SNs. This method is particularly valuable when radioisotope tracers or other blue dyes are unavailable.
Key Study Components
Area of Science
- Breast cancer surgery
- Surgical oncology
- Pathology
Background
- Sentinel node biopsy is a standard procedure for staging axillary lymph nodes in breast cancer.
- Commonly, radioisotope tracers or patent/isosulfan blue dyes are used for SN identification.
- Resource limitations may restrict access to these agents in some settings.
- Methylene blue dye offers a cost-effective alternative for SNB.
Purpose of Study
- To demonstrate the feasibility and technique of using 1% methylene blue dye alone for SNB in breast cancer.
- To provide a step-by-step protocol for SN identification and pathological assessment.
- To highlight the utility of MBD when other tracers or dyes are unavailable.
Methods Used
- Preparation and injection of 1% methylene blue dye into the subareolar or peritumoral space.
- Identification of SNs via blue staining and lymphatic channels during BCS (through a separate axillary incision) or mastectomy (through the mastectomy incision).
- Use of anatomical landmarks in the axilla to aid SN identification.
- Intraoperative frozen section analysis and histopathological examination of SNs.
Main Results
- Sentinel nodes were successfully identified as blue nodes or nodes with blue lymphatic channels.
- The technique was applicable in both BCS and mastectomy procedures.
- Pathological evaluation confirmed the presence or absence of metastases in SNs.
- MBD alone was effective for SNB when other tracers were not available.
Conclusions
- 1% methylene blue dye is a viable single-agent technique for sentinel node biopsy in breast cancer.
- This method is especially useful in resource-limited settings.
- Accurate SN identification and pathological assessment can be achieved without radioisotopes or other blue dyes.
Frequently Asked Questions
Executive Industry Relevance
Reliable sentinel node identification is critical for early-stage breast cancer staging and surgical decision-making. The use of 1% methylene blue dye as a standalone technique addresses resource limitations and ensures continuity of axillary staging when radioisotope tracers or other blue dyes are unavailable. This approach supports portfolio-wide risk management and operational flexibility in diverse clinical and research settings.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables robust interrogation of lymphatic involvement in breast cancer models.
- Supports functional validation of sentinel node mapping without reliance on radioisotopes.
- Facilitates biological de-risking in preclinical and translational research environments.
Screening & Assay Development
- Provides a standardized, reproducible method for sentinel node identification in tissue-based assays.
- Delivers clear, visual endpoints for quantitative assessment of lymphatic mapping.
- Enables assay scalability and platform reuse in settings with limited tracer access.
Translational & Preclinical Research
- Aligns with disease-relevant models for axillary staging and metastasis evaluation.
- Ensures continuity from discovery through preclinical validation in breast cancer research.
- Supports risk-adjusted advancement decisions by providing reliable nodal status data.
Pipeline & Workflow Integration
This technique integrates into the discovery-to-preclinical continuum, supporting both early-stage hypothesis testing and translational validation of lymphatic involvement in breast cancer.
- Discovery Biology: Enables hypothesis-driven testing of lymphatic spread and sentinel node involvement.
- Screening: Provides reproducible, quantitative outputs for node identification and mapping.
- Analytics: Supports intraoperative and histopathological readouts for comparative analysis.
- Translational Research: Bridges discovery findings with preclinical and clinical staging workflows.
- Enterprise Reuse: Offers a cost-effective, adaptable technique for diverse research and clinical portfolios.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence in nodal staging and target validation.
- Operational Value: Increases standardization, reproducibility, and accessibility across sites.
- Strategic Value: Improves go/no-go decision-making and reduces late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of breast cancer programs.
Implementation Considerations
- Requires expertise in surgical technique and anatomical landmark identification.
- Needs access to intraoperative frozen section and histopathology infrastructure.
- Demands cross-team standardization for reproducible node identification.
- Adaptable to both breast conserving surgery and mastectomy models.
- Dependent on visual detection, which may limit sensitivity compared to dual-tracer methods.
Biopharma FAQs
Chapters in this video
0:00
Title
1:42
Preparation of 1% Methylene Blue Dye and the Injection Technique
2:27
Sentinel Node Biopsy Technique in Breast Conserving Surgery
3:15
Sentinel Node Biopsy Technique in Mastectomy
4:26
Pathological Examination of Sentinel Nodes
5:09
Intraoperative Examination
6:16
Results
6:56
Conclusion
